Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report

Mostrar otras versiones (1)

Dolutegravir (DTG), an integrase strand transfer inhibitor is currently the recommended first and second line anti-retroviral therapy (ART) anchor agent by the World Health Organization due to its favorable side effect profile, high efficacy and genetic barrier to resistance. Despite its very good s...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulindwa, Frank, Castelnuovo, Barbara, Brusselaers, Nele, Bollinger, Robert, Yendewa, George, Amutuhaire, Willington, Mukashaka, Claudine, Schwarz, Jean-Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617153/
https://www.ncbi.nlm.nih.gov/pubmed/37904127
http://dx.doi.org/10.1186/s12879-023-08712-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617153/
https://www.ncbi.nlm.nih.gov/pubmed/37904127
http://dx.doi.org/10.1186/s12879-023-08712-z

Ejemplares similares